Safety Study of Levocetirizine and Fexofenadine

Phase 4

Completed

• Conditions: Pruritus; Chronic Urticaria; Allergic Rhinitis
• Interventions: Drug: Placebo Oral Tablet; Drug: Levocetirizine Oral Tablet; Drug: Fexofenadine 60 Mg Oral Tablet

• Registration Number: NCT01586091
• Lead Sponsor: Charite University, Berlin, Germany

Brief Summary

This Study is to comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg once daily with Fexofenadine 60 mg twice daily in the histamine induced wheal, flare and itch Response.

Detailed Description

This will be a randomized, double-blind, placebo-controlled study with intra-individual comparison of the histamine induced wheal and flare reaction. In September 2009, Fexofenadine was approved as an antihistamine against allergies in Japan and it is currently used widely. It has been approved in 120 countries, including the US, UK, France and Germany \[11\]. In Europe and the United States, fexofenadine is marketed at 120 mg once daily for allergic rhinitis and 180mg once daily for urticaria. In Japan, fexofenadine is marketed at 60 mg twice daily for both conditions. But is this dosage regimen as effective as levocetirizine, 5 mg once daily? The above described study from Takahashi et al, comparing 60 mg twice daily versus cetirizine 10 mg once daily suggests that it is not \[4\]. The aim of the study is to compare the efficacy and consistency of action of levocetirizine 5 mg once daily with fexofenadine 60 mg twice daily over a 24 hour period in the histamine induced wheal, flare and itch response. Furthermore, we would like to investigate whether a different between Japanese and Caucasian exists or not. Each volunteer will receive the study medication at time point 0 and 12 hour later. Skin Prick Test (SPT) will be performed in each volunteer using histamine (10 mg/ml), 15 minutes before drug admission (baseline) and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours afterwards. Volumetric optical scanning system and infrared camera will be used for objective evaluation of the wheal- and flare reduction. Additionally, measurement of the erythema diameter with a transparent ruler will be performed. The subjective intensity of itching will be assessed using a Visual Analogue Scale (VAS). To relate the pharmacokinetics of the drugs to their pharmacodynamics, blood samples for assay of drug concentrations will be taken at baseline and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours later. Subjects will undergo the same procedure on three separate occasions to receive each treatment option. The options are: placebo at time 0 hours + placebo at 12 hours, Levocetirizine 5mg at time 0 hours + placebo at 12 hours or fexofenadine 60mg at time 0 hours + fexofenadine 60mg at 12 hours. There will be a washout period of at least 6 days between the treatments.

Study Timeline

• Study Start: 2011-02
• Primary Completion: 2011-11
• Study Completion: 2012-02
• Study First Submitted: 2012-04-23
• Study First Submitted QC: 2012-04-24
• Study First Posted: 2012-04-26
• Results First Submitted: 2016-01-29
• Status Verified: 2019-09
• Results First Submitted QC: 2019-09-15
• Last Update Submitted: 2019-09-15
• Results First Posted: 2019-10-04
• Last Update Posted: 2019-10-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 18

Inclusion Criteria

Eighteen (18) healthy male volunteers, including at least 6 persons of Japanese origin, will be recruited for this study

Exclusion Criteria

• None of the subjects will have taken oral antihistamines, antidepressants, antipsychotics or corticosteroids or applied topical antihistamines, corticosteroids or mast cell stabilizers to the skin for 2 weeks prior to testing.
• No subject shall perform physical exercise for 4 hours prior to the skin prick testing.
• Especially, Bronchial asthma, anaphylactic reactions in the history, use of beta-blockers, skin diseases in the test field are exclusion criteria.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo Oral Tablet	Placebo per os at time 0 hours + placebo per os at 12 hours.
Levocetirizin	Levocetirizine Oral Tablet	Levocetirizin 5mg at time 0 and placebo per os at 12 hours
Levocetirizin	Placebo Oral Tablet	Levocetirizin 5mg at time 0 and placebo per os at 12 hours
Fexofenadine	Fexofenadine 60 Mg Oral Tablet	Fexofenadine 60mg per os at time 0 hours + fexofenadine 60mg per os at 12 hours

Primary Outcome Measures

Name	Time	Method
Pruritus as Assessed by the VAS Score	up to 10 minutes after skin prick test performed 24 hours after drug administration	We measured drug concentrations and various aspects of skin provocation testing such as itch intensity and wheal size. Measurements made at each time point were as followed: Pruritus was assessed every 30 s for 10 min after SPT using a visual analogue scale (VAS) score with a "0" and "100" at the two ex- tremes of an unmarked 100 mm line with higher values indicating greater puritus. The mean VAS for each 10 min was calculated and used as a primary end Point.
Flaire Diameter (mm)	24 hours per treatment	Flaire diameter was measured with a transparent ruler as the mean of the largest diameter and the diameter at right angles to this.
Wheal Volume (cm3)	24 hours per treatment	Wheal volume was measured by a non-contact three dimensional measurement system (PRIMOS contact, GFM Messtechnik GmbH, Teltow, Germany).

Trial Locations

Locations (1)

University of Berlin Charité, Department of Dermatology and Allergy; 🇩🇪 Berlin, Germany